ReviewThe World Allergy Organization journal2023
The multifactorial impact of receiving a hereditary angioedema diagnosis.
Review in The World Allergy Organization journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1.Journal of asthma and allergy · 2026Trial
- Exposure-Response Analysis of Donidalorsen for the Treatment of Hereditary Angioedema.Clinical and translational science · 2025Trial
- Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema.Allergy · 2025Trial
- Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER/ENABLE.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Trial
- Psychometric validation of the Angioedema Quality of Life Questionnaire (AE-QoL) for hereditary angioedema.Journal of patient-reported outcomes · 2026Article
- A novel SERPING1 splice-site variant (c.1029 + 2T > A) causing hereditary angioedema type I: functional characterization and clinical analysis.Orphanet journal of rare diseases · 2026Article
- Patient Preferences for Long-Term Prophylactic Treatment in Hereditary Angioedema: A Discrete-Choice Experiment.The patient · 2026Article
- Advances in hereditary angioedema in the modern treatment era in China: a focus on diagnosis, treatment, and prognosis.Orphanet journal of rare diseases · 2026Review
- Burden of disease in adult patients with hereditary angioedema: results from a multinational survey.Orphanet journal of rare diseases · 2026Article
- Burden of hereditary angioedema: results from a multinational survey of caregivers for adult and pediatric patients.Orphanet journal of rare diseases · 2026Article
- The patient experience of hereditary angioedema: findings from a racially diverse sample of adult patients.Orphanet journal of rare diseases · 2026Article
- Population Pharmacokinetic/Pharmacodynamic Modeling of Donidalorsen, an Antisense Oligonucleotide in Development for Prophylaxis of Hereditary Angioedema.CPT: pharmacometrics & systems pharmacology · 2026Article
- Clinical features of hereditary angioedema involving the gastrointestinal tract: A retrospective analysis.The World Allergy Organization journal · 2026Article
- Donidalorsen for the Treatment of Hereditary Angioedema: A Review of Clinical Studies.Drug design, development and therapy · 2026Review
- Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema.Clinical and translational allergy · 2026Article
- A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.Frontiers in immunology · 2026Article
- Unmet needs in hereditary angioedema: an international survey of physicians.Orphanet journal of rare diseases · 2025Article
- Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis.Journal of comparative effectiveness research · 2025Article
- Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial.The World Allergy Organization journal · 2024Article
- A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary angioedema (HAE) is a rare, chronic, debilitating genetic disorder characterized by recurrent, unpredictable, and potentially life-threatening episodes of swelling that typically affect the extremities, face, abdomen, genitals, and larynx. The most frequent cause of HAE is a mutation in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.